Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Distribution of HCV Genotypes Among People Who Inject Drugs in Tunisia: New Evidence for Scaling Up Prevention and Treatment Toward National Elimination Goal

A. Chouikha, A. Ghrabi, A. Ghodbane, W. Hammemi, M. Khedhiri, A. Sadraoui, H. Touzi, HB. Hassine, S. Maatoug, C. Bensaoud, S. Abdelhak, S. Bouarrouj, M. Gdoura, H. Chaouachi, H. Triki

. 2021 ; 12 (-) : 697859. [pub] 20210727

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024300

Little is known about the distribution of hepatitis C virus (HCV) genotypes among people who inject drugs (PWID) in North African countries, including Tunisia. This study aims to describe HCV genotypes circulating among Tunisian PWID. A cross-sectional study was conducted, and 128 HCV-positive PWID were recruited between 2018 and 2019 from community-based harm reduction centers. After informed consent, sociodemographic characteristics and risk behavior data were obtained using an interviewer-administrated questionnaire. Blood samples were collected for further serological and molecular testing. Overall, five women and 123 men were included. The median age was 39.5 years. The majority of PWID (56.3%) had less than a secondary level of education, were single (57%), were unemployed (65.6%), were incarcerated at least once (93.0%), and had a history of residency in at least one foreign country (50.8%). During the previous 12 months, 82.0% reported having reused syringes at least once, 43.8% shared syringes at least once, while 56.2% had at least one unprotected sexual relation, and 28.1% had more than two different sexual partners. Tattooing was reported among 60.2%. All positive results for HCV-infection by rapid testing were confirmed by enzyme-linked immunosorbent assay (ELISA). HCV-RNA was detectable in 79.7%. Genotyping showed a predominance of genotype 1 (52%) followed by genotype 3 (34%) and genotype 4 (10%). Four patients (4%) had an intergenotype mixed infection. Subtyping showed the presence of six different HCV subtypes as follows: 1a (53.2%), 1b (6.4%), 3a (33.0%), 4a (3.2%), and 4d (4.3%). This is the first study describing circulating HCV genotypes among PWID in Tunisia. The distribution of HCV genotypes is distinct from the general population with a predominance of subtypes 1a and 3a. These findings can be used to guide national efforts aiming to optimize the access of PWID to relevant HCV prevention and treatment measures including pangenotypic regimens for patients infected with HCV genotype 3.

000      
00000naa a2200000 a 4500
001      
bmc21024300
003      
CZ-PrNML
005      
20211013133959.0
007      
ta
008      
211006s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fmicb.2021.697859 $2 doi
035    __
$a (PubMed)34385988
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Chouikha, Anissa $u Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, Tunis El Manar University, Tunis, Tunisia
245    10
$a Distribution of HCV Genotypes Among People Who Inject Drugs in Tunisia: New Evidence for Scaling Up Prevention and Treatment Toward National Elimination Goal / $c A. Chouikha, A. Ghrabi, A. Ghodbane, W. Hammemi, M. Khedhiri, A. Sadraoui, H. Touzi, HB. Hassine, S. Maatoug, C. Bensaoud, S. Abdelhak, S. Bouarrouj, M. Gdoura, H. Chaouachi, H. Triki
520    9_
$a Little is known about the distribution of hepatitis C virus (HCV) genotypes among people who inject drugs (PWID) in North African countries, including Tunisia. This study aims to describe HCV genotypes circulating among Tunisian PWID. A cross-sectional study was conducted, and 128 HCV-positive PWID were recruited between 2018 and 2019 from community-based harm reduction centers. After informed consent, sociodemographic characteristics and risk behavior data were obtained using an interviewer-administrated questionnaire. Blood samples were collected for further serological and molecular testing. Overall, five women and 123 men were included. The median age was 39.5 years. The majority of PWID (56.3%) had less than a secondary level of education, were single (57%), were unemployed (65.6%), were incarcerated at least once (93.0%), and had a history of residency in at least one foreign country (50.8%). During the previous 12 months, 82.0% reported having reused syringes at least once, 43.8% shared syringes at least once, while 56.2% had at least one unprotected sexual relation, and 28.1% had more than two different sexual partners. Tattooing was reported among 60.2%. All positive results for HCV-infection by rapid testing were confirmed by enzyme-linked immunosorbent assay (ELISA). HCV-RNA was detectable in 79.7%. Genotyping showed a predominance of genotype 1 (52%) followed by genotype 3 (34%) and genotype 4 (10%). Four patients (4%) had an intergenotype mixed infection. Subtyping showed the presence of six different HCV subtypes as follows: 1a (53.2%), 1b (6.4%), 3a (33.0%), 4a (3.2%), and 4d (4.3%). This is the first study describing circulating HCV genotypes among PWID in Tunisia. The distribution of HCV genotypes is distinct from the general population with a predominance of subtypes 1a and 3a. These findings can be used to guide national efforts aiming to optimize the access of PWID to relevant HCV prevention and treatment measures including pangenotypic regimens for patients infected with HCV genotype 3.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ghrabi, Amine $u Association Tunisienne d'Information et d'Orientation sur le SIDA et la Toxicomanie (Tunisian Association for Information and Orientation on HIV/AIDS and Toxicomania - ATIOST), Tunis, Tunisia
700    1_
$a Ghodbane, Amira $u Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, Tunis El Manar University, Tunis, Tunisia
700    1_
$a Hammemi, Walid $u Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, Tunis El Manar University, Tunis, Tunisia
700    1_
$a Khedhiri, Marwa $u Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, Tunis El Manar University, Tunis, Tunisia
700    1_
$a Sadraoui, Amel $u Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, Tunis El Manar University, Tunis, Tunisia
700    1_
$a Touzi, Henda $u Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, Tunis El Manar University, Tunis, Tunisia
700    1_
$a Hassine, Hichem Ben $u Science Shop, Institut Pasteur de Tunis, Tunis, Tunisia
700    1_
$a Maatoug, Sonia $u Science Shop, Institut Pasteur de Tunis, Tunis, Tunisia
700    1_
$a Bensaoud, Chaima $u Science Shop, Institut Pasteur de Tunis, Tunis, Tunisia $u Institute of Parasitology, Biology Centre, Czech Academy of Sciences, Ceske Budejovice, Czechia
700    1_
$a Abdelhak, Sonia $u Science Shop, Institut Pasteur de Tunis, Tunis, Tunisia
700    1_
$a Bouarrouj, Samir $u Association Tunisienne d'Information et d'Orientation sur le SIDA et la Toxicomanie (Tunisian Association for Information and Orientation on HIV/AIDS and Toxicomania - ATIOST), Tunis, Tunisia
700    1_
$a Gdoura, Mariem $u Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, Tunis El Manar University, Tunis, Tunisia
700    1_
$a Chaouachi, Hedia $u Association Tunisienne d'Information et d'Orientation sur le SIDA et la Toxicomanie (Tunisian Association for Information and Orientation on HIV/AIDS and Toxicomania - ATIOST), Tunis, Tunisia
700    1_
$a Triki, Henda $u Laboratory of Clinical Virology, WHO Reference Laboratory for Poliomyelitis and Measles in the Eastern Mediterranean Region, Pasteur Institute of Tunis, Tunis El Manar University, Tunis, Tunisia
773    0_
$w MED00181714 $t Frontiers in microbiology $x 1664-302X $g Roč. 12, č. - (2021), s. 697859
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34385988 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013133956 $b ABA008
999    __
$a ind $b bmc $g 1708269 $s 1144797
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 12 $c - $d 697859 $e 20210727 $i 1664-302X $m Frontiers in microbiology $n Front Microbiol $x MED00181714
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...